AstraZeneca plans to build $1.5B manufacturing facility for ADCs in Singapore

AstraZeneca intends to build a $1.5B manufacturing facility in Singapore for antibody drug conjugates, ADCs, enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody. The planned greenfield facility, supported by the Singapore Economic Development Board, EDB, will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale. As part of AstraZeneca’s commitment to driving sustainability in healthcare, the Company will work with Singapore’s government and other partners on green solutions for the ADC facility. This facility will be designed to emit zero carbon from its first day of operations. AstraZeneca aims to begin design and construction of the manufacturing facility by the end of 2024, with targeted operational readiness from 2029.